PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SLA Pharma

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SLA Pharma AG Reports Successful Phase 3 Results for Treatment of Anal Fissure - S.L.A. Pharma AG has announced positive results from its 465 patient Phase 3 study with Anoheal™ for treatment of anal fissure - SLApharma.com
SLA Pharma AG Reports Successful Phase 3 Results for Treatment of Anal Fissure

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/05/21 - S.L.A. Pharma AG has announced positive results from its 465 patient Phase 3 study with Anoheal™ for treatment of anal fissure - SLApharma.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

S.L.A. Pharma AG has announced positive results from its 465 patient Phase 3 study with Anoheal™, a novel topical formulation of diltiazem. Anoheal™ 2% cream was superior to placebo in reducing anal pain and improving quality of life for patients suffering from anal fissure.

Anoheal™ displayed statistically significant results after 4 weeks compared to placebo for the primary and secondary endpoints. The results showed a reduction in worst anal pain associated with or following defecation (p =0.013), and in overall daily anal pain (p =0.018), and there was an increase in the Patient’s Global Impression of Improvement (p =0.011). After eight weeks of treatment there was significantly greater anal fissure healing for patients receiving Anoheal™ (p =0.036). Reduction in pain was rapid and sustained over the eight week treatment period. Anoheal™ was well tolerated with no differences in treatment emergent adverse events compared to placebo.

Dr Elliot Bland, Head of Business Development commented “The results from this Phase 3 trial have confirmed that Anoheal significantly improves pain and healing for patients suffering from anal fissure. We already have licensees in North America, Western and Central Europe; we’re now seeking licensing partners in other territories.”

“This represents an extremely successful period for SLA Pharma with positive results achieved in both this Phase 3 trial and our Phase 2 study for treatment of opioid induced constipation.” stated CEO, Justin Slagel.

About S.L.A. Pharma AG

S.L.A. Pharma AG (slapharma.com) is a privately owned Swiss company pioneering the development of speciality pharmaceutical products for gastrointestinal and rare disorders. Their pipeline consists of Phase 2 and Phase 3 developments for indications with unmet clinical needs such as anal fissure, symptoms of Crohn’s disease, opioid induced constipation, familial adenomatous polyposis, and faecal incontinence. S.L.A. Pharma forms partnerships with other pharmaceutical companies with sales and marketing expertise to commercialise their products.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SLA Pharma

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SLA Pharma AG Reports Successful Phase 3 Results for Treatment of Anal Fissure

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Elliot Bland - SLApharma.com 
+44(0)19 2368 1001 ebland[.]slapharma.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SLA Pharma securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SLA Pharma / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)